Concord Biotech (CONCORDBIO) Q1 24/25 earnings summary

Executive summary

• Achieved 11% year-on-year revenue growth in Q1 FY25, reaching ₹215.8 crore, with profit before tax up 20% year-on-year (ex-JV), EBITDA up 13%, and PAT up 9%.

• Formulation segment revenue surged 43% year-on-year, while API revenue grew 5%.

• Maintained strong market position through backward integration, broad fermentation-based API portfolio, and leadership in immunosuppressant APIs.

• Management remains optimistic, focusing on deeper market penetration, new product launches, and R&D in oncology, anti-infectives, and antibacterial segments.

• Upcoming injectable facility expected to be commercialized by Q4 FY25, enhancing end-to-end capabilities.

Financial highlights

• Q1 FY25 revenue: ₹215.8 crore (up 11% YoY); EBITDA: ₹81.3 crore (up 13% YoY); PAT: ₹59.6 crore (up 9% YoY).

• API revenue: ₹171.05 crore (5% growth YoY); Formulation revenue: ₹44.75 crore (43% growth YoY).

• Gross profit margin: 77.6%; EBITDA margin: 38%; PAT margin: 27.6%.

• EPS for Q1 FY25 at ₹5.7, up from ₹5.2 in Q1 FY24.

• Standalone and consolidated results reviewed and approved by Board and auditors, with no material misstatements.

Outlook and guidance

• Long-term revenue CAGR guidance of 25% over five years, driven by new product launches and capacity expansion.

• Focus on expanding in developed and emerging markets, with plans to commercialize 8-10 new products over 3-4 years.

• API/formulation business mix expected to remain at 80/20, with no change to long-term margin guidance.

• Exploring CDMO opportunities and continued investment in R&D.

• Commercialization of new injectable plant expected to drive growth from next year.